REALQUALITY RQ-PML-RARα bcr1 One-Step

REALQUALITY RQ-PML-RARα bcr1 One-Step is a molecular diagnostic kit developed by AB Analitica (Italy).
It is designed for the detection and quantification of the PML-RARα bcr1 transcript, which is associated with
Acute Promyelocytic Leukemia (APL) and the t(15;17) translocation.
This kit uses a One-Step Real-Time RT-PCR format that enables fast, efficient, and highly accurate molecular testing.

The detection of the bcr1 isoform is essential in APL diagnostics because it provides clinicians with reliable molecular
markers for early diagnosis and treatment monitoring. The One-Step workflow reduces manual steps, prevents contamination,
and ensures consistent amplification. As a result, laboratories benefit from reproducible results and a simplified
diagnostic process.

Technical Features of REALQUALITY RQ-PML-RARα bcr1 One-Step

Specific detection of the t(15;17)(q24;q21) translocation, bcr1 variant
Developed in line with international guidelines for APL molecular testing
Includes a dUTP/UNG system to prevent PCR carryover contamination
Contains an internal fluorescent normalizer for assay quality control
Requires only 5 μL of extracted RNA for each reaction
Ideal for treatment response monitoring and MRD detection
Compatible with all major Real-Time PCR platforms

Clinical Applications of REALQUALITY RQ-PML-RARα bcr1 One-Step

Detection of PML-RARα bcr1 transcripts in APL patients
Monitoring Minimal Residual Disease (MRD) levels
Evaluating treatment response throughout therapy
Supporting consistent molecular follow-up in hematology laboratories

🇮🇹 About AB Analitica

AB Analitica is a leading Italian manufacturer of advanced molecular diagnostic kits.
All products are developed in full compliance with European clinical and quality standards, ensuring
high analytical performance and long-term reliability in diagnostic workflows.

🇮🇷 Exclusive Distributor in Iran

Fardad Azma Rad Co. is the exclusive representative of AB Analitica
in Iran. The company provides REALQUALITY RQ-PML-RARα bcr1 One-Step to molecular diagnostic laboratories nationwide.
Services include:

Certified authenticity for all imported kits
Expert training for laboratory per

Additional Information:
The t(15;17)(q22;q21) translocation is commonly associated with Acute Promyelocytic Leukemia (APL), a subtype of Acute Myeloid Leukemia (AML) classified as M3 morphology. APL accounts for approximately 10-15% of AML cases. This translocation results from the fusion of the PML gene on chromosome 15 and the RARa (Retinoic Acid Receptor alpha) gene on chromosome 17. Breakpoints in these genes occur in different regions, producing specific PML-RARa isoforms named bcr1, bcr2, and bcr3. The fusion protein blocks differentiation of hematopoietic stem cells, arresting them at the promyelocyte stage. Treatment with ATRA (All-Trans Retinoic Acid) is highly effective in APL by promoting differentiation.